drugset / Trial / NCT02276768
Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates colonic analgesia by comparing two novel formulations, GIC-1001 and GIC-1002 with placebo using a barostat distender. The healthy male and female volunteers randomized to one of 5 possible treatments will be exposed to rectal distension following a 3-day treatment TID. The barostat methodology is a well-established and validated way to assess visceral pain. Visceral pain will be evaluated during exposure to varying distender pressures using a visual analog scale.
Timeline
- Start
- 2014-10
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GIC-1002 | Unknown | 345 mg | Oral |
| Comparator | GIC-1002 | Unknown | 460 mg | Oral |
| Subject | trimebutine 3-thiocarbamoylbenzenesulfonate | Small molecule | 375 mg | Oral |
| Subject | trimebutine 3-thiocarbamoylbenzenesulfonate | Small molecule | 500 mg | Oral |